AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1341206
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate 75 mg daily for 6 months
Trial: 1341206
Drug: Almitrine combined
RxNorm normalized name: almitrine
DrugBank: Almitrine (DB01430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine combined with oxygen (8-10 L/min)
Trial: 6605310
Drug: Tinoridine 200
RxNorm normalized name: Tinoridine
DrugBank: Tinoridine (DB13001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinoridine 200 mg
Trial: 6605310
Drug: Tinoridine 400
RxNorm normalized name: Tinoridine
DrugBank: Tinoridine (DB13001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinoridine 400 mg
Trial: 6605310
Drug: Tinoridine 800
RxNorm normalized name: Tinoridine
DrugBank: Tinoridine (DB13001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinoridine 800 mg
Trial: 6605310
Drug: Tinoridine 200
RxNorm normalized name: Tinoridine
DrugBank: Tinoridine (DB13001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinoridine 200 mg (patients with renal disease)
Trial: 29716563
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract (2 × 18.5 mg PACs per day)
Trial: 29716563
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract (37 mg PACs per day)
Trial: 29716563
Drug: Control dose
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control dose (2 × 1 mg PACs per day)
Trial: 29716563
Drug: Control dose
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control dose (2 mg PACs per day)
Trial: 26821189
Drug: PG201 (600mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG201 (600mg, 300mg twice daily)
Trial: 26821189
Drug: SKI306X (600mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKI306X (600mg, 200mg thrice daily)
Trial: 23518215
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (MP) at 32 mg/day for seven days
Trial: 23518215
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (MP) at 1 mg/kg/day for four days and 0.5 mg/kg/day for three days
Trial: 23518215
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (MP)
Trial: 23518215
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (MP)
Trial: 19356394
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (XM02) at 5 microg/kg
Trial: 19356394
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (XM02) at 10 microg/kg
Trial: 12044859
Drug: Vinpocetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine (20 mg in 500 ml saline)
Trial: 12044859
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 ml saline)
Trial: 7652726
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of magnesium
Trial: 25978942
Drug: Mannitol cream
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol cream
Trial: 25978942
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream (without mannitol)
Trial: 16475633
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine with fentanyl (20 microg) at a conventional high dose of 0.07 mg cm(‐1) (group 1)
Trial: 16475633
Drug: 0.25% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% levobupivacaine with fentanyl (20 microg) and epidural volume extension with 6 mL of saline (group 2)
Trial: 11189545
Drug: Vacuum-assisted closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-assisted closure (V.A.C.) therapy
Trial: 9728231
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate via metered dose inhaler (MDI)
Trial: 3489445
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 500 mg twice a day and dipyridamole 75 mg three times a day
Trial: 30950493
Drug: Azithromycin (20/mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (20/mg/kg single dose)
Trial: 30316695
Drug: Propofol (1–4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1–4 mg kg−1)
Trial: 30316695
Drug: Alfaxalone (0.5–2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (0.5–2 mg kg−1)
Trial: 23167308
Drug: MHBA grafted
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHBA grafted (TG) - buccal plate thickness ≤ 1 mm (TG-a)
Trial: 23167308
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - buccal plate thickness ≤ 1 mm (CG-a)
Trial: 23167308
Drug: MHBA grafted
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHBA grafted (TG) - buccal plate thickness > 1 mm (TG-b)
Trial: 23167308
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - buccal plate thickness > 1 mm (CG-b)
Trial: 18844761
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (valsartan + hydrochlorothiazide)
Trial: 18844761
Drug: Monotherapy (valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (valsartan alone)
Trial: 16036126
Drug: Specimens immersed
RxNorm normalized name: SPECIMEN CONTAINER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specimens immersed in coffee solution
Trial: 8942455
Drug: Social skills
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social skills training with active drug supplementation
Trial: 8942455
Drug: Supportive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive group therapy with active drug supplementation
Trial: 8942455
Drug: Supportive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive group therapy with placebo supplementation
Trial: 1840324
Drug: Teicoplanin 15
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 15 mg/Kg iv
Trial: 1840324
Drug: Teicoplanin 20
RxNorm normalized name: Teicoplanin 200 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 20 mg/Kg iv
Trial: 1840324
Drug: Teicoplanin 25
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 25 mg/Kg iv
Trial: 7078016
Drug: Coded commercial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coded commercial artificial tear solution 1
Trial: 7078016
Drug: Coded commercial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coded commercial artificial tear solution 2
Trial: 7078016
Drug: Coded commercial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coded commercial artificial tear solution 3
Trial: 7078016
Drug: Coded commercial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coded commercial artificial tear solution 4
Trial: 28657703
Drug: Oral gel
RxNorm normalized name: Oral Gel
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gel
Trial: 28657703
Drug: Mouth spray
RxNorm normalized name: Moi-Stir Dry Mouth Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouth spray
Trial: 26534729
Drug: Tailored practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored practice and patient plans; training sessions for practitioners in medication prescribing and behavioural change; regular patient recall system.
Trial: 23432339
Drug: Melatonin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin administered at 0.1 μg kg(‐1) h(‐1) for 2 hours
Trial: 23432339
Drug: Population pharmacokinetics
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Population pharmacokinetics of melatonin
Trial: 21450183
Drug: Oral extended-release
RxNorm normalized name: Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral extended-release oxybutynin 5 mg
Trial: 15826410
Drug: Routine GP
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine GP treatment (Control)
Trial: 9871862
Drug: Timolol hemihydrate
RxNorm normalized name: Timolol Hemihydrate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol hemihydrate 0.5% solution once daily
Trial: 9871862
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate gel 0.5% once daily
Trial: 8717212
Drug: rH‐EPO 9,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rH‐EPO 9,000 IU intravenously daily
Trial: 8717212
Drug: rH‐EPO (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rH‐EPO (various doses)
Trial: 2142293
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (IB), 250 micrograms inhalation solution
Trial: 343728
Drug: Sulindac (300-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (300-400 mg daily)
Trial: 30269430
Drug: ISBB (Interscalene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISBB (Interscalene Brachial Plexus Block) with 20 mL of 0.25% bupivacaine
Trial: 30269430
Drug: SCBB (Supraclavicular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCBB (Supraclavicular Brachial Plexus Block) with 20 mL of 0.25% bupivacaine
Trial: 25969414
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) tablets, 60 mg (treatment A)
Trial: 25969414
Drug: Powder formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder formulation delivered to the distal small bowel (treatment B)
Trial: 25969414
Drug: Powder formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder formulation delivered to the ascending colon (treatment C)
Trial: 25969414
Drug: Aqueous suspension
RxNorm normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous suspension delivered to the ascending colon (treatment D)
Trial: 25969414
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) tablets, 30 mg (treatment E)
Trial: 25969414
Drug: Granulate formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulate formulation with fumaric acid 50 mg delivered to the ascending colon (treatment F)
Trial: 21846929
Drug: Phenylephrine and
RxNorm normalized name: phenylephrine and ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine and epinephrine spray group
Trial: 17882140
Drug: Tyrosine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine (400 mg)
Trial: 17882140
Drug: Green Tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green Tea Extract (500 mg)
Trial: 15630270
Drug: Concord grape
RxNorm normalized name: Concord Grape
DrugBank: Concord grape (DB10875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concord grape juice (CGJ) 5.5 ml/kg body weight/day for 8 weeks
Trial: 9203227
Drug: Cortisol infusion
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol infusion (15 mg hydrocortisone sodium succinate over 120 min)
Trial: 3295501
Drug: Moderate-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Moderate-dose methotrexate
Trial: 3295501
Drug: Both high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both high-dose and moderate-dose methotrexate
Trial: 26280790
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (28,000 IU)
Trial: 12732840
Drug: Cremophor RH40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cremophor RH40 (600 mg 3 times daily)
Trial: 3857359
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g CTM, given 4 times daily for 5 days (Group A)
Trial: 3857359
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g CTM, given twice daily for 5 days (Group B)
Trial: 24953794
Drug: Rituximab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (both dosing arms)
Trial: 22180589
Drug: SmokeStop Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SmokeStop Therapy (SST)
Trial: 19904250
Drug: Double-dosed pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dosed pantoprazole (40 mg twice daily for 8 weeks)
Trial: 19904250
Drug: Standard-dosed pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dosed pantoprazole (40 mg per day for 8 weeks and one blank tablet at night)
Trial: 15954953
Drug: Propofol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (30 mg boluses every second minute)
Trial: 15954953
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide (N2O, premedication with 30 mg propofol 5 min before, increased every other minute in 15% increments, max. 75%)
Trial: 8835706
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram (CIT) 40 to 60 mg daily for 4 weeks
Trial: 8835706
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram (CIT) with lithium carbonate (Li) 2 x 400 mg/day from days 29 to 35
Trial: 8835706
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram (CIT) with lithium (Li) 800 mg/day from days 36 to 42
Trial: 6486112
Drug: Breakfast containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast containing greater than 30 g fat
Trial: 6486112
Drug: Breakfast containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast containing less than 15 g fat
Trial: 6486112
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of C‐terminal octapeptide of cholecystokinin
Trial: 26857421
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care with additional low dose chest CT
Trial: 25127679
Drug: Fecal immunochemical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal immunochemical tests (FITs), 3 tests (1/year for 3 years), cutoff ≥10 μg hemoglobin/g feces
Trial: 18061756
Drug: Relaxation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation and visualization therapy (RVT) for 24 consecutive days
Trial: 9487345
Drug: Diffumal‐24 (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diffumal‐24 (once daily at 20.00 hours)
Trial: 9487345
Drug: Theo‐Dur (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo‐Dur (twice daily at 08.00 and 20.00 hours)
Trial: 8149942
Drug: Buffered aspirin
RxNorm normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buffered aspirin (700 mg)
Trial: 8149942
Drug: Aspirin with
RxNorm normalized name: Bayer Aspirin with Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin with calcium carbonate (700 mg)
Trial: 8149942
Drug: Aspirin with
RxNorm normalized name: Bayer Aspirin with Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin with caffeine (700 mg)
Trial: 29519353
Drug: Etidronate (cyclical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (cyclical 20 mg/kg for 2 weeks every 12 weeks)
Trial: 16181528
Drug: Simple Western
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Western medicine
Trial: 14616429
Drug: Melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (6 mg) alone
Trial: 14616429
Drug: Melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (6 mg) with caffeine (3 x 200 mg)
Trial: 9282610
Drug: SL Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SL Nifedipine 10 mg
Trial: 9282610
Drug: SL Captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SL Captopril 25 mg
Trial: 9282610
Drug: IV Metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Metoprolol 15 mg
Trial: 1658591
Drug: LAK cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAK cells injected i.a on days 10, 14, and 21 after operation with IL-2 injections during 3 weeks.
Trial: 1658591
Drug: Adriamycin treatment
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin treatment only (Control group).
Trial: 23566246
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg daily for two months followed by an individually matched dose of 10 or 20 mg/day (group A)
Trial: 23566246
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group B) treated according to current recommendations without statin therapy
Trial: 18830045
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 treatment
Trial: 10047932
Drug: Immediate-release carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release carbidopa/levodopa (Sinemet, IR-CL)
Trial: 10047932
Drug: Controlled-release carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release carbidopa/levodopa (Sinemet CR, CR-CL)
Trial: 8559497
Drug: rHuEpo treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo treatment
Trial: 8559497
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no rHuEpo treatment)
Trial: 30860474
Drug: Thymopentin (TP5)
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (TP5) add-on therapy for 24 weeks with entecavir (ETV) and peginterferon alfa-2a (PegIFN alpha-2a)
Trial: 23388507
Drug: Remifentanil (0-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0-10 ng ml(‐1)) and sevoflurane (0.3-3.4 vol.%)
Trial: 11903835
Drug: Cisapride 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 0.2 mg/kg four times a day for 7 days
Trial: 2906367
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg iv dose administered by constant-rate infusion over 30 min
Trial: 2906367
Drug: Oral doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of 10 mg, 20 mg, and 40 mg
Trial: 2906367
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg iv dose, 10 mg oral dose, 20 mg oral dose, 40 mg oral dose
Trial: 25535011
Drug: SSRI medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI medication regimen
Trial: 23087419
Drug: Subconjunctival bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subconjunctival bevacizumab (2.5 mg in 0.1 ml injections)
Trial: 18212687
Drug: Combined intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined intra-arterial (IA) plus intramuscular (IM) administration of autologous bone marrow mononuclear cells (BMC)